Key Takeaways CVS stock is up nearly 50% YTD, driven by strong Q1 results and rising investor confidence. The Senate dropped PBM and Medicare cuts, lifting a key overhang for CVS's Caremark and Aetna units. CVS raised 2025 EPS guidance to $6.00-$6.20 after segment-wide growth and operational efficiency.CVS Health Corporation (CVS) is gaining investor attention as the stock trends higher ahead of its second-quarter earnings release, scheduled for July 30, 2025. A key catalyst behind the recent uptick occur ...

Walgreens is set to go private after shareholder approval of its takeover. (Photo by Spencer ... More Platt/Getty Images)Getty ImagesWalgreens Boots Alliance Inc. has taken a major step forward in its bid to go private after it announced that at the Company’s Special Meeting of Shareholders, WBA shareholders had approved the previously announced acquisition of the company by entities affiliated with Sycamore Partners Management.According to the preliminary results, approximately 96% of votes cast at the Spe ...

Omnicell Investor & Analyst Day 2019 Las Vegas, NV December 10, 2019 Safe Harbor Statement To the extent any statements contained in this presentation deal with information that is not historical, these statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those ...

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce the expansion of its HealthTab™ platform into pharmacies in North Central London—making it the second NHS Integrated Care Board (ICB), after North East London, to join this groundbreaking initiative aimed at tackling health inequalities through cholesterol screening. Six (6) new HealthTab™ systems were deployed in this phase, expanding the UK network to thirte ...

Wall Street banks including JPMorgan and UBS have begun early pricing discussions with investors for a $4.25 billion debt package to help finance Sycamore Partners' buyout of UK pharmacy Boots https://t.co/VpQzXN9Bdq ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's future growth potential based on earnings and sales [4] - Momentum Score evaluates stocks based on price trends and earnings estimate changes [5] - VGM Score combines the three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in stock selection [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [9][10] Company Spotlight: CVS Health - CVS Health Corporation, a pharmacy innovation company, is currently rated 1 (Strong Buy) on the Zacks Rank with a VGM Score of A [11] - The company has a Value Style Score of A, supported by a forward P/E ratio of 10.95, indicating strong valuation metrics [12] - Recent earnings estimates for fiscal 2025 have been revised upward, with the Zacks Consensus Estimate increasing by $0.04 to $6.12 per share, alongside an average earnings surprise of +18.1% [12]

WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a leading Medicare Advantage company committed to affordable, high-quality care, today announced the launch of a new community-based pharmacy pilot program across New Jersey. Built in partnership with IPC Digital Health™, a division of Independent Pharmacy Cooperative (IPC), this initiative is designed to help seniors better manage their medications and stay healthier at home, supported by ...

NEWTOWN, Pa., July 07, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving PetMed Express, Inc. (“PetMed”) (NASDAQ: PETS), resulting from allegations of providing potentially misleading business information to the investing public. If you have non-public information that could assist in the PetMed investigation, or if you are a PetMed investor who suffered a loss and would like to learn more, you can provide your information HERE. You ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Core Viewpoint - PetMed Express, Inc. has received a notice from Nasdaq regarding non-compliance with listing rules due to the late filing of its Annual Report on Form 10-K for the fiscal year ending March 31, 2025 [1][3]. Group 1: Compliance and Filing Status - The notice indicates that the company must submit a plan to regain compliance within 60 days, by September 1, 2025, and may receive an extension of up to 180 days to regain compliance [3]. - The company filed a Notification of Late Filing on Form 12b-25, stating it was unable to file the Form 10-K on time due to ongoing efforts to compile and analyze necessary financial information [3][4]. - The company is working diligently to complete its financial statements and plans to file the Form 10-K as soon as possible to regain compliance with Nasdaq listing rules [4]. Group 2: Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, operating as a national online pharmacy licensed across all 50 states [5]. - The company offers a comprehensive range of pet health solutions, including pharmaceuticals, compounded medications, and OTC supplements, focusing on value, convenience, and care for pet wellness [5].